India drug price cuts expected to hit hard; Sun, Glenmark approved for generic Rilutek; Maine OKs mail-order drug buys;

@FiercePharma: Needy Forest Labs reportedly eyes a bid for Elan. But why? Yesterday's story | Follow @FiercePharma

@EricPFierce: Who manufactures the top selling diabetes treatments? Novo has 5 of top 10, but not the top two. Special report | Follow @EricPFierce

> The U.S. Department of Justice has sued Sage Pharmaceuticals, a Shreveport, LA, company it says has been selling unapproved drugs over-the-counter. Release

> The FDA Thursday approved Abbott's ($ABT) RealTime HCV Genotype II test to identify the genotype of hepatitis C virus (HCV) that patients are carrying, which will help doctors decide what treatment they should receive. Announcement | More from FierceMedicalDevices

> Price cuts on 151 essential drugs in India are expected to have a huge impact on the drug industry there. Report

> India's Sun Pharmaceutical Industries and Glenmark Generics say they have been approved by the FDA to make generic versions of Sanofi ($SNY) myotrophic lateral sclerosis treatment Rilutek. Report

> The Maine legislature has approved a bill to permit citizens to buy prescription drugs from mail-order pharmacies in Canada, the U.K., New Zealand and Australia. Story

Medical Device News

@FierceMedDev: Endo's AMS owes $54.5M in vaginal mesh lawsuit. News | Follow @FierceMedDev

@DamianFierce: Philips' is enduring its third ventilator recall in about a year, drawing a deadly FDA warning. Report | Follow @DamianFierce

@MichaelGFierce: Biosensor nanoparticles deliver cancer drug with precise, 3-D imaging. FierceDrugDelivery story | Follow @MichaelGFierce

> GE pads mammography prowess with Korean buyout. Story

> Abbott wins FDA nod for hep C gene test. Article

> France ponies up for study of GI Dynamics' obesity tech. More

> Medtronic ups dividend, eyes share buyback. Item

Biotech News

@FierceBiotech: ICYMI: 10 startups fueling pharma in social media. Special report | Follow @FierceBiotech

 @JohnCFierce: Under review and well past Ph3: Can Novartis gain anything from its latest breakthrough drug win at the FDA? Article | Follow @JohnCFierce

@RyanMFierce: The news: Ablynx heads to PhI w/ German Merck. The takeaway: Misspell Merck Serono, and it rhymes with 'My Sharona." Story | Follow @RyanMFierce

 @EmilyMFierce: New at Penn scientists create human-cell model of pancreatic cancer. Story | Follow @EmilyMFierce

> J&J spreads deal-making net with global ring of satellite offices. More

> Takeda asks FDA to OK its potential inflammatory bowel disease blockbuster. News

> Idenix plunges after FDA throws up a roadblock for lead hep C 'nuc.' Report

And Finally... A report says that approval of the anticoagulent Eliquis from Bristol-Myers Squibb ($BMY) and Pfizer ($PFE) was held up for 9 months by trial study issues. Report